Compugen Ltd
Suletud
2.6 -5.11
Ülevaade
Aktsiahinna muutus
24h
Min
2.58
Max
2.62
Sissetulek | 663K -7M |
|---|---|
Müük | 426K 2.6M |
P/E Sektori keskmine | 6.816 57.366 |
Aktsiakasum | -0.07 |
Kasumimarginaal | -269.254 |
Töötajad | 75 |
EBITDA | 665K -7M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +92.31% upside |
Järgmine tulemuste avaldamine | 9. nov 2026 |
|---|
Turukapital | 20M 245M |
|---|---|
Eelmine avamishind | 7.71 |
Eelmine sulgemishind | 2.6 |
Compugen Ltd Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Compugen Ltd Prognoos
Hinnasiht
By TipRanks
92.31% tõus
12 kuu keskmine prognoos
Keskmine 5 USD 92.31%
Kõrge 6 USD
Madal 4 USD
Põhineb 2 Wall Streeti analüütiku instrumendi Compugen Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Compugen Ltd
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
